Absci accelerates ABS-201 in alopecia & endometriosis, targets data by 2027, and refocuses pipeline for value.

On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 Expanding ABS-201 strategy to pursue endometriosis as additional ...

Absci Corp (ABSI) focuses on advancing ABS-201 trials while seeking partnerships for ABS-101, backed by a robust cash reserve to fund operations into 2028.

The latest announcement is out from AbSci ( (ABSI) ).

A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new ...

“That’s one of the most common myths I hear, and it’s not true,” says Dr. Jerry Shapiro, dermatologist, hair loss, and ...

A prospective trial found that autologous platelet-rich plasma injections significantly improved hair density and ...

Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadershipPhase 1/2a trial now expected to begin in ...

Over their lifetime, about half of men and 40% of women will experience alopecia, or hair loss. Understanding what type of alopecia a person has can make a big ...

This article was reviewed by Knox Beasley, MD. Rogaine vs Minoxidil: What’s Best for Hair Growth? Growing up, you may have ...

An international expert panel developed guidelines on the diagnosis and management of persistent chemotherapy-induced alopecia.

This article was reviewed by Knox Beasley, MD. Exosomes for Hair Loss: Costs, Safety, Efficacy, & Benefits The deeper you research options for hair loss treatments, ...